187 related articles for article (PubMed ID: 22564186)
1. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
[TBL] [Abstract][Full Text] [Related]
2. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
Gupta SK; Kizilbash SH; Carlson BL; Mladek AC; Boakye-Agyeman F; Bakken KK; Pokorny JL; Schroeder MA; Decker PA; Cen L; Eckel-Passow JE; Sarkar G; Ballman KV; Reid JM; Jenkins RB; Verhaak RG; Sulman EP; Kitange GJ; Sarkaria JN
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26615020
[TBL] [Abstract][Full Text] [Related]
3. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization.
Liu J; Wang K; Zhu Q; Zhang Y; Chen Y; Lou Z; Yuan J
CNS Neurosci Ther; 2024 Apr; 30(4):e14711. PubMed ID: 38644551
[TBL] [Abstract][Full Text] [Related]
4. Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma.
Tiek DM; Rone JD; Graham GT; Pannkuk EL; Haddad BR; Riggins RB
Sci Rep; 2018 May; 8(1):7222. PubMed ID: 29740146
[TBL] [Abstract][Full Text] [Related]
5. EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
Xin L; Tan Y; Zhu Y; Cui X; Wang Q; Zhao J; Tian S; Xu C; Xiao M; Hong B; Xu J; Yuan X; Wang C; Kang C; Fang C
Neuro Oncol; 2023 Nov; 25(11):1976-1988. PubMed ID: 37279651
[TBL] [Abstract][Full Text] [Related]
6. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.
Zapanta Rinonos S; Li T; Pianka ST; Prins TJ; Eldred BSC; Kevan BM; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
J Neurooncol; 2024 Jan; 166(1):129-142. PubMed ID: 38224404
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.
Liang BB; Wang YH; Huang JJ; Lin S; Mao GC; Zhou ZJ; Yan WJ; Shan CY; Wu HZ; Etcheverry A; He YL; Liu FF; Kang HF; Yin AA; Zhang SQ
CNS Neurosci Ther; 2024 Apr; 30(4):e14465. PubMed ID: 37830163
[TBL] [Abstract][Full Text] [Related]
8. EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma.
Yang E; Hong B; Wang Y; Wang Q; Zhao J; Cui X; Wu Y; Yang S; Su D; Liu X; Kang C
Cancer Lett; 2024 Apr; 588():216812. PubMed ID: 38490327
[TBL] [Abstract][Full Text] [Related]
9. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
Yip S; Miao J; Cahill DP; Iafrate AJ; Aldape K; Nutt CL; Louis DN
Clin Cancer Res; 2009 Jul; 15(14):4622-9. PubMed ID: 19584161
[TBL] [Abstract][Full Text] [Related]
10. FoxM1-mediated RFC5 expression promotes temozolomide resistance.
Peng WX; Han X; Zhang CL; Ge L; Du FY; Jin J; Gong AH
Cell Biol Toxicol; 2017 Dec; 33(6):527-537. PubMed ID: 28185110
[TBL] [Abstract][Full Text] [Related]
11. Kinomic exploration of temozolomide and radiation resistance in Glioblastoma multiforme xenolines.
Anderson JC; Duarte CW; Welaya K; Rohrbach TD; Bredel M; Yang ES; Choradia NV; Thottassery JV; Yancey Gillespie G; Bonner JA; Willey CD
Radiother Oncol; 2014 Jun; 111(3):468-74. PubMed ID: 24813092
[TBL] [Abstract][Full Text] [Related]
12. A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT.
Brown CC; Havener TM; Medina MW; Auman JT; Mangravite LM; Krauss RM; McLeod HL; Motsinger-Reif AA
Pharmacogenet Genomics; 2012 Nov; 22(11):796-802. PubMed ID: 23047291
[TBL] [Abstract][Full Text] [Related]
13. Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells.
Park I; Mukherjee J; Ito M; Chaumeil MM; Jalbert LE; Gaensler K; Ronen SM; Nelson SJ; Pieper RO
Cancer Res; 2014 Dec; 74(23):7115-24. PubMed ID: 25320009
[TBL] [Abstract][Full Text] [Related]
14. Targeting autophagy to sensitive glioma to temozolomide treatment.
Yan Y; Xu Z; Dai S; Qian L; Sun L; Gong Z
J Exp Clin Cancer Res; 2016 Feb; 35():23. PubMed ID: 26830677
[TBL] [Abstract][Full Text] [Related]
15. mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.
Weiler M; Blaes J; Pusch S; Sahm F; Czabanka M; Luger S; Bunse L; Solecki G; Eichwald V; Jugold M; Hodecker S; Osswald M; Meisner C; Hielscher T; Rübmann P; Pfenning PN; Ronellenfitsch M; Kempf T; Schnölzer M; Abdollahi A; Lang F; Bendszus M; von Deimling A; Winkler F; Weller M; Vajkoczy P; Platten M; Wick W
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):409-14. PubMed ID: 24367102
[TBL] [Abstract][Full Text] [Related]
16. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
Oliveira-Ferrer L; Hauschild J; Fiedler W; Bokemeyer C; Nippgen J; Celik I; Schuch G
J Exp Clin Cancer Res; 2008 Dec; 27(1):86. PubMed ID: 19114005
[TBL] [Abstract][Full Text] [Related]
17. Histone Methylation by Temozolomide; A Classic DNA Methylating Anticancer Drug.
Wang T; Pickard AJ; Gallo JM
Anticancer Res; 2016 Jul; 36(7):3289-99. PubMed ID: 27354585
[TBL] [Abstract][Full Text] [Related]
18. Glioblastoma-derived cells
Witusik-Perkowska M; Zakrzewska M; Sikorska B; Papierz W; Jaskolski DJ; Szemraj J; Liberski PP
Biosci Rep; 2017 Jun; 37(3):. PubMed ID: 28522553
[TBL] [Abstract][Full Text] [Related]
19. Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma.
Head RJ; Fay MF; Cosgrove L; Y C Fung K; Rundle-Thiele D; Martin JH
Cancer Biol Ther; 2017 Dec; 18(12):917-926. PubMed ID: 29020502
[TBL] [Abstract][Full Text] [Related]
20. Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro Sampling.
Morelli M; Lessi F; Franceschi S; Ferri G; Giacomarra M; Menicagli M; Gambacciani C; Pieri F; Pasqualetti F; Montemurro N; Aretini P; Santonocito OS; Di Stefano AL; Mazzanti CM
Cells; 2024 Mar; 13(6):. PubMed ID: 38534332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
